LoginSignup
Kuros Bioscience logo

Kuros Bioscience Stock

StockStock
ISIN: CH0325814116
Ticker: KURN
CH0325814116
KURN

Price

Frequently asked questions

What is Kuros Bioscience's market capitalization?

The market capitalization of Kuros Bioscience is $1.23B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Kuros Bioscience?

Kuros Bioscience's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.26. EPS indicates the company's profitability on a per-share basis.

What is Kuros Bioscience's revenue over the trailing twelve months?

Over the trailing twelve months, Kuros Bioscience reported a revenue of $59.59M.

What is the EBITDA for Kuros Bioscience?

Kuros Bioscience's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$7.44M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Kuros Bioscience?

Kuros Bioscience has a free cash flow of -$3.70M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Kuros Bioscience's stock?

The 5-year beta for Kuros Bioscience is 1.14. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Kuros Bioscience have, and what sector and industry does it belong to?

Kuros Bioscience employs approximately 80 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Kuros Bioscience's shares?

The free float of Kuros Bioscience is 25.61M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $1.23B

5Y beta

 1.14

EPS (TTM)

 -$0.26

Free Float

 25.61M

Revenue (TTM)

 $59.59M

EBITDA (TTM)

 -$7.44M

Free Cashflow (TTM)

 -$3.70M

Pricing

1D span
$32.11$33.44

Information

Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

80

Biotechnology & Drugs

Health Care

Identifier

ISIN

CH0325814116

Primary Ticker

KURN

Knockouts

Join the conversation
Sign upLogin